Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × Ferrosoferric Oxide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 4 Brain Neoplasms 4 Esophageal Neoplasms 3 Urinary Bladder Neoplasms 2 Prostatic Neoplasms 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Childhood Brain Neoplasm 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rectal Neoplasms 1 Pancreatic carcinoma, familial 1 Pancreatic Neoplasms 1 Pancreatic Intraductal Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Osteonecrosis 1 Osteomyelitis 1 Neurodegenerative Diseases 1 Neoplasms 1 Malignant Solid Neoplasm 1 Lung Carcinoma Metastatic in the Brain 1 Liver Neoplasms 1 Liver Cirrhosis 1 Kidney Neoplasms 1 Ischemic Stroke 1

Interventions

Doxorubicin 120 Ifosfamide 70 Radiotherapy 65 Cyclophosphamide 61 Gemcitabine 53 Filgrastim 46 Trabectedin 36 pazopanib 34 Docetaxel 34 Etoposide 33 pembrolizumab 32 Vincristine 30 Cisplatin 29 Nivolumab 27 Irinotecan 21 Magnetic Resonance Spectroscopy 20 Carboplatin 20 Ipilimumab 19 Surgical Procedures, Operative 18 Radiation 18 Temozolomide 17 Mesna 16 Melphalan 16 Biopsy 16 Bevacizumab 16 Sirolimus 15 Granulocyte Colony-Stimulating Factor 15 Drug Therapy 15 Dactinomycin 15 Blood Specimen Collection 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01663090 2020-10-19

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

Dana-Farber Cancer Institute

Phase NA Withdrawn

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡